Know Cancer

forgot password

Phase II Trial of Lithium as a Neuroprotective Agent for Patients With Small Cell Lung Cancer (SCLC) Treated With Prophylactic Cranial Irradiation (PCI)

Phase 2
18 Years
Open (Enrolling)
Small Cell Lung Carcinoma

Thank you

Trial Information

Phase II Trial of Lithium as a Neuroprotective Agent for Patients With Small Cell Lung Cancer (SCLC) Treated With Prophylactic Cranial Irradiation (PCI)

Inclusion Criteria:

- Patient must have histologically or cytologically confirmed small cell lung cancer.
Patients with either limited or extensive stage disease are eligible.

- Patient must have completed 4-6 cycles of platinum-based chemotherapy (+/- thoracic

- Patient must have no evidence of progressive disease on restaging imaging within 3
months of enrollment

- For patients taking medications known to have a significant interaction with lithium
carbonate, these medications should be discontinued at least 1 week prior to and
during lithium treatment

- Patient must be > or = 18 years old.

- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of
=< 2

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT])
=< 3.0 x IULN

- Creatinine within normal institutional limits OR creatinine clearance >= 50
mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

- Patient must have an electrocardiogram without evidence of arrhythmia, QT
prolongation (QTc > 450 ms in males and > 470 ms in females), or other severe
dysfunction within 2 weeks of initiation of lithium

- Women of childbearing potential (women with regular menses, women with amenorrhea,
women with irregular cycles, women using a contraceptive method that precludes
withdrawal bleeding, and women who have had a tubal ligation) are required to have a
negative urine pregnancy test within 14 days prior to the first dose of lithium.

- Women of childbearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control, abstinence) prior to study entry and
for the duration of study participation; should a woman become pregnant or suspect
she is pregnant while participating in this study, she must inform her treating
physician immediately

- Patient (or legally authorized representative if applicable) must be able to
understand and willing to sign an Internal Review Board (IRB) approved written
informed consent document

Exclusion Criteria:

- Patient must not have history of prior cranial radiotherapy

- Patient must not have brain metastases present prior to initiation of initial therapy
or PCI

- Patient must not have evidence of progressive disease

- Patient must not have received chemotherapy within 3 weeks of initiation of PCI

- Patient must not have a history of other malignancy =< 2 years previous with the
exception of basal cell or squamous cell carcinoma of the skin which were treated
with local resection only or carcinoma in situ of the cervix

- Patient must not be actively receiving any other investigational agents

- Patient must not have a history of allergic reactions attributed to compounds of
similar chemical or biologic composition to lithium carbonate

- Patient must not have any uncontrolled intercurrent illness including, but not
limited to, ongoing or active infection symptomatic congestive heart failure,
unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
situations that would limit compliance with study requirements

- Patient must not have any uncontrolled thyroid disease

- Patient must not have a seizure disorder

- Patient must not be pregnant and/or breastfeeding

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Outcome Measure:

Dose-limiting toxicities of lithium (DLTs), (safety lead-in)

Outcome Description:

Graded and described using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4. Safety will be defined as < 2 patients experiencing DLTs of the first 6 treated.

Outcome Time Frame:

3 weeks

Safety Issue:


Principal Investigator

Clifford Robinson, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Washington University School of Medicine


United States: Institutional Review Board

Study ID:




Start Date:

April 2012

Completion Date:

April 2015

Related Keywords:

  • Small Cell Lung Carcinoma
  • Carcinoma
  • Lung Neoplasms
  • Small Cell Lung Carcinoma



Washinton University School of Medicine St. Louis, Missouri  63110